- Moderna (MRNA +4.6%) plans to test a booster shot of its COVID-19 vaccine after the initial two-dose immunization, as the duration of protection from the vaccine is still unknown, CNBC reports.
- “I think this will become a market like flu,” Moderna CEO Stephane Bancel told CNBC.
- The company is poised to initiate the trial in July this year. Trial sites have started contacting participants from earlier studies, citing an e-mail shared by one of those people.
- “From what we’ve seen so far, I think our expectation is that the vaccination should last you at least a year,” Moderna’s chief medical officer, Dr. Tal Zaks said at the JPMorgan Healthcare Conference, according to CNBC.
- Participants who received lower doses than the authorized 100 mg would get boosters earlier, while those on 100 micrograms or higher would get their shot at the year mark.
- Moderna's CEO said that COVID-19 is likely to become an endemic disease.